2022 Influenza Vaccine Production & Distribution Market Report
Part 1 Of 3
The U.S. saw an extended 2021-2022 flu season, continuing through June 2022. States lifting COVID-19 restrictions, children’s return to in-person learning, and employees returning to the office all contributed to the prolonged flu season. As the Southern Hemisphere reports the highest flu rates since 2017, the U.S. prepares for a potentially difficult 2022-2023 flu season. The 2022 HIDA Influenza Vaccine Report’s first of three preview reports provides insights into the upcoming flu season including:
- An estimated 171.5 million doses of the influenza vaccine will be manufactured for the upcoming season.
- Influenza A accounted for 96.7% of influenza hospitalizations last season.
- A higher dosage flu vaccine has been recommended for adults 65 and older.
Free for members; members only
Members: Click below to log in and download the report as a PDF.